Sr. Director of R&D Business Operations Biogen
Daniel Rosan is a health care strategist & operator with 15 years of experience bringing innovative therapies to patients in the private & nonprofit sectors.
As head of Biogen’s R&D Resource & Performance Management team, Dan drives R&D capital expenditures, resource and portfolio planning, portfolio prioritization and management, and project management support for Biogen’s portfolio of investigational neurology therapeutic products. He also leads the R&D integration process for companies acquired by Biogen.
Dan recently drove the External Innovation component of Biogen’s Portfolio Transformation efforts, identifying innovative ways to generate & finance external innovation. He has served on the TYSABRI and SPINRAZA program teams, assessed multiple business development and M&A transactions, advised on multi-billion dollar capital allocation decisions, and led Biogen’s financial long range planning process.
Prior to joining Biogen, Dan consulted with Frankel Group (acquired by Huron Consulting in 2014), a boutique firm serving biotechnology companies and investors. There he supported top-5 biopharmaceutical companies as well as top tier venture capital funds. He led the Interfaith Center on Corporate Responsibility’s health care practice for four years, with a focus on HIV/AIDS treatment access.